Baker Julian's Form 4 filing
Celcuity Inc. (CELC) · filed Jul 16, 2026
- Accession no.
- 0001193125-26-306299
- Filed
- Jul 16, 2026, 5:42 PM ET
- Trade date
- Jul 14, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $317.8M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Baker JulianCIK 0001087939 | Other: Former 10% owner |
| Baker FelixCIK 0001087940 | Other: Former 10% owner |
| Baker Bros. Advisors LPCIK 0001263508 | Other: Former 10% owner |
| Baker Bros. Advisors (GP) LLCCIK 0001580575 | Other: Former 10% owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 14, 2026 | Common Stock | SSaleDisposed | −261,368 | $102.50 | −$26,790,220 | 442,940 | Indirect | |
| Jul 14, 2026 | Common Stock | SSaleDisposed | −2,838,632 | $102.50 | −$290,959,780 | 4,372,852 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
On July 14, 2026, Baker Bros. Advisors LP on behalf of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"), submitted written notice to Celcuity Inc. (the "Issuer") to set the beneficial ownership limitation (the "Maximum Percentage") with respect to 481,437 and 5,666,350 prefunded warrants to purchase common stock of the Issuer ("Common Stock") at an exercise price of $0.001 per share held by 667 and Life Sciences, respectively, at 9.99%. As a result of the transactions reported herein and the setting of the Maximum Percentage at 9.99%, the reporting persons no longer beneficially own greater than 10% of the Common Stock.